THOUSAND OAKS, Calif., Jan. 28, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2025 financial results on Tuesday, February 3, 2026, after the close of the U.S. financial markets. The announcement will be followed by a...
LAS VEGAS--(BUSINESS WIRE)--Sagebrush Health Services, a nonprofit organization serving over 10,000 Nevada patients, has filed a lawsuit against Amgen Inc. (NASDAQ: AMGN), alleging that Amgen acted unlawfully by unilaterally terminating the sale of discounted drugs to Sagebrush’s clinics and improperly retracting millions of dollars in past discounts. These actions, Sagebrush maintains, temporarily prevented it from supplying its clinics with necessary medications from Amgen and other manufactu
Lead candidate in the MLLT1/3 programme, DBT 3757, is a differentiated investigational molecule designed to treat Acute Myeloid Leukemia Acquisition brings a new therapeutic mechanism to Amgen's extensive cancer portfolio – Dark Blue has pioneered the biology of targeting MLLT1/3, and DBT...
Underscores Long-Standing Commitment to Investing in Innovation and U.S. Manufacturing THOUSAND OAKS, Calif., Dec. 19, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced it is taking action again with the U.S. government to lower medicine costs for American patients, while...
Study Also Shows 36% Reduction in Risk of Heart Attack Repatha is the First and Only PCSK9 Inhibitor to Significantly Reduce the Risk of First Heart Attack and Stroke THOUSAND OAKS, Calif., Nov. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3...
(NASDAQ:AMGN) DOONBEG, Ireland, Sept. 10, 2025 /PRNewswire/ -- The Trump Organization and Trump International Golf Links® & Hotel Ireland, Doonbeg, are thrilled to announce, in conjunction with the DP World Tour, that the prestigious Amgen Irish Open will be held at Trump International Golf Links &...
(NASDAQ:AMGN) THOUSAND OAKS, Calif., Sept. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 9:15 a.m. ET on September 9, 2025. Peter Griffith, executive vice president and chief financial officer at Amgen, and Kave Niksefat,...
(NASDAQ:AMGN) Research and Development Infrastructure Investment Expected to Create Hundreds of U.S. Jobs THOUSAND OAKS, Calif., Sept. 2, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced plans to invest more than $600 million in a new, state-of-the-art center for science and innovation at its...
(NASDAQ:AMGN) THOUSAND OAKS, Calif., Aug. 29, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2025 Wells Fargo Healthcare Conference at 10:15 a.m. ET on Wednesday, Sept. 3, 2025. Paul Burton, M.D., Ph.D, senior vice president and chief medical officer at Amgen, will present at the...
THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to include adults at increased risk for major adverse cardiovascular events (MACE) due to...
Shares of Amgen (AMGN) have been trending lower with the Health Care sector. But the sell off may soon come to an end.
Cathie Wood highlights the rising applications of AI and how it is poised to impact the health care space.
What Happened: On Sunday, President Donald Trump announced on Truth Social that he plans to sign what he called the "most consequential executive order" in U.S. history, aimed at lowering prescription drug prices.
BeiGene posted a surprise Q1 profit and $1.12 billion in revenue, with strong U.S. Brukinsa sales, while reaffirming its 2025 outlook and margin guidance.
Analysts highlight MariTide's upcoming updates and near-term catalysts, while Amgen's price targets shift amid steady outlook and investor caution.
Lilly's weight-loss drug trial shows promising results, propelling stock up 14.36%. Goldman Sachs predicts potential $23.5B in sales by 2035.
Sandoz sues Amgen in U.S. court over Enbrel patents, alleging efforts to block biosimilar Erelzi and delay competition in the inflammatory disease market.
President Donald Trump has declared that his administration is on the brink of imposing a significant tariff on pharmaceuticals imported from foreign countries.
Dip-buying absent in early NY trading, Wall Street deep in red as trade war fears escalate despite strong jobs report. Investors on edge for hints from Fed Chair Powell.
The FDA approved Amgen's Uplizna as the first treatment for IgG4-RD. The decision is backed by the MITIGATE trial, showing reduced flares and sustained efficacy.
